🟢 ANI Pharmaceuticals is trading 5% up in pre-market on Egetis offer valued at approximately $560 million

ANI Pharmaceuticals is trading at $75.49, up +5.36%, after announcing a recommended offer to acquire Egetis Therapeutics for approximately $560 million.

• The deal expands ANI’s rare-disease business; Egetis’s board unanimously recommended the offer.
• ANI’s Q3 results are scheduled for 8:00 a.m. ET on November 5; no results were available in the cited reporting.